Millstone Evans Group’s AstraZeneca AZN Stock Holding History

Millstone Evans Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21	Closed	-$3.86K	–	859
2025 Q4	$3.86K	Hold	21	–	–	﹤0.01%	678
2025 Q3	$3.22K	Hold	21	–	–	﹤0.01%	688
2025 Q2	$2.94K	Sell	21 -31	-60%	-$4.34K	﹤0.01%	639
2025 Q1	$7.57K	Buy	52 +31	+148%	+$4.49K	0.01%	550
2024 Q4	$2.75K	Buy	+21	New	+$2.94K	﹤0.01%	624

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Millstone Evans Group's AZN Position: Q1 2026 in Review

Millstone Evans Group sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 21 shares — an estimated $3.86K sold.

Millstone Evans Group first reported a position in AZN in Q4 2024 and held it in 5 quarters. The position peaked at $7.57K in Q1 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Millstone Evans Group reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Millstone Evans Group sold 21 AstraZeneca shares in Q1 2026, an estimated $3.86K.
Millstone Evans Group first reported a position in AstraZeneca in Q4 2024 and held it in 5 quarters.
Millstone Evans Group's AstraZeneca position peaked at $7.57K in Q1 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Millstone Evans Group's 13F filing for Q1 2026, filed 30 Apr 2026.